文献速递类风湿关节炎脊柱关节炎

特定肿瘤坏死因子抑制剂暴露与炎症性关节炎患者队列中脱髓鞘及炎症性神经病风险:一项跨越五个北欧风湿病登记处的协作观察性研究

Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers.
PubMed 文献 · RMD Open · 2023-01-01

该观察性队列研究纳入2001-2020年间五个北欧国家开始肿瘤坏死因子抑制剂(TNFi)治疗的类风湿关节炎(RA)和脊柱关节炎(SpA)患者,比较单克隆TNFi抗体(oTNFi)与依那西普的神经炎症事件发生率。结果显示SpA中神经炎症事件粗发生率高于RA,但特定TNFi选择似乎不显著影响神经炎症事件风险。

要点

  • RA中oTNFi与依那西普相比,任何神经炎症事件HR 1.07(95%CI 0.74-1.54),无显著差异。
  • RA中IPN的HR 2.20(95%CI 1.05-4.63),oTNFi组高于依那西普组。
  • SpA中神经炎症事件粗发生率为oTNFi组0.68 vs 依那西普组0.65/1000人年,HR无显著差异。

核心结论

  • SpA中神经炎症事件粗发生率高于RA,但特定TNFi选择似乎不显著影响神经炎症事件风险。

研究设计与样本

  • 观察性队列研究,纳入2001-2020年五个北欧国家开始TNFi治疗的RA和SpA患者。

主要发现

  • RA纳入33883例患者,启动52704个疗程,观察到135例神经炎症事件(65%为DML),oTNFi组cIR 0.38 vs 依那西普组0.34。
  • RA中oTNFi vs 依那西普的HR:任何神经炎症事件1.07(95%CI 0.74-1.54),DML 0.79(95%CI 0.51-1.22),IPN 2.20(95%CI 1.05-4.63),MS 0.73(95%CI 0.34-1.56)。
  • SpA纳入28772例患者,启动46572个疗程,观察到179例事件(78%为DML),oTNFi组cIR 0.68 vs 依那西普组0.65。
  • SpA中oTNFi vs 依那西普的HR:任何神经炎症事件1.06(95%CI 0.75-1.50),DML 1.01(95%CI 0.68-1.50),IPN 1.28(95%CI 0.61-2.69),MS 0.94(95%CI 0.53-1.69)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare incidences of neuroinflammatory events, including demyelinating disease (DML), inflammatory polyneuropathies (IPN) and multiple sclerosis (MS), in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA; including psoriatic arthritis) starting a tumour necrosis factor inhibitor (TNFi), investigating whether monoclonal TNFi antibodies (other TNFis (oTNFis)) confer higher risk than etanercept. METHODS: This is an observational cohort study including patients from the five Nordic countries starting a TNFi in 2001-2020. Time to first neuroinflammatory event was identified through register linkages. We calculated crude incidence rates (cIR) per 1000 person-years and used multivariable-adjusted Cox regression to compare incidences of neuroinflammatory events overall and for DML, IPN and MS with oTNFi versus etanercept. We further examined individual TNFis and indications. RESULTS: 33 883 patients with RA and 28 772 patients with SpA were included, initiating 52 704 and 46 572 treatment courses, respectively. In RA, we observed 135 neuroinflammatory events (65% DML) with cIR of 0.38 with oTNFi and 0.34 with etanercept. The HR of oTNFi versus etanercept was 1.07 (95% CI 0.74 to 1.54) for any neuroinflammatory event, 0.79 (95% CI 0.51 to 1.22) for DML, 2.20 (95% CI 1.05 to 4.63) for IPN and 0.73 (95% CI 0.34 to 1.56) for MS. In SpA, we observed 179 events (78% DML) with cIR of 0.68 with oTNFi and 0.65 with etanercept. The HR for any neuroinflammatory event, DML, IPN and MS was 1.06 (95% CI 0.75 to 1.50), 1.01 (95% CI 0.68 to 1.50), 1.28 (95% CI 0.61 to 2.69) and 0.94 (95% CI0.53 to 1.69), respectively. CONCLUSION: The cIRs of neuroinflammatory events are higher in SpA than in RA, but the choice of specific TNFi does not seem to play an important role in the risk of neuroinflammatory events.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Delcoigne B, Kopp TI, Arkema EV, et al. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers. RMD Open. 2023. PMID: 36854568. doi:10.1136/rmdopen-2022-002924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。